Please login to the form below

Not currently logged in
Email:
Password:

PD-1 inhibitor

This page shows the latest PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

GSK upbeat on its return to oncology market

GSK upbeat on its return to oncology market

Along with Zejula, Tesaro also brings with it a pipeline PD-1 inhibitor, TSR-022. ... The company already has Zeluja in combination trials with TSR-022, with all the established PD-1 players also pursuing similar PARP inhibitor combinations.

Latest news

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Nektar disclosed data from the PIVOT trial of NKTR-214 plus BMS’ PD-1 inhibitor Opdivo (nivolumab) at the ASCO meeting last year, although the two companies were forced to defend ... He also revealed that Nektar has agreed to test NKTR-214 with

  • AZ still sees route to approval for Imfinzi in MYSTIC trial AZ still sees route to approval for Imfinzi in MYSTIC trial

    biomarker also being used by Bristol-Myers Squibb) to make a case for its PD-1 inhibitor Opdivo (nivolumab) after it also failed in first-line NSCLC. ... roles of PD-L1 expression and TMB in determining the efficacy of immunotherapy.

  • BMS to test Vedanta’s bacterial therapy with Opdivo BMS to test Vedanta’s bacterial therapy with Opdivo

    Squibb’s PD-1 inhibitor Opdivo. ... In animal studies presented at this year’s Society for Immunotherapy of Cancer (SITC) meeting, VE800 on its own and alongside PD-1 inhibitors showed anti-tumour effects, including cytotoxic T

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    of the year – gives GSK rights to approved PARP inhibitor Zejula (niraparib), which is jostling for market share with AstraZeneca's Lynparza (olaparib) and Clovis Oncology's Rubraca (rucaparib). ... They point to the potential of pipeline candidates

  • Loxo, Bayer get FDA okay for biomarker-driven cancer drug Loxo, Bayer get FDA okay for biomarker-driven cancer drug

    Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its PD-1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a ... It will also test patients for another mutation – RET

More from news
Approximately 3 fully matching, plus 188 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Pharma deals in September 2015 Pharma deals in September 2015

    taking rights (outside China) to a PD-1 inhibitor (POC ready) from Jaingsu Hengrui Medicine (SHR-1210) for advanced solid tumours paying a modest $25m upfront but up to $770m in ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

  • Pharma deals during October 2014 Pharma deals during October 2014

    Medivation closed an exclusive worldwide licence with rights to CureTech's pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody. ... The phase 1/2 studies will assess Novartis' Zykadia [ceritinib], INC 280 and EGF 816 in combination

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics